Things For Investors To Watch In AbCellera Biologics Inc (NASDAQ: ABCL)

AbCellera Biologics Inc (NASDAQ:ABCL) does about 1.58M shares in volume on a normal day but saw 1552043 shares change hands in Monday trading. The company now has a market cap of 808.64M USD. Its current market price is $2.75, marking an increase of 2.23% compared to the previous close of $2.69. The 52 week high reached by this stock is $8.05 whilst the lowest price level in 52 weeks is $2.66.

AbCellera Biologics Inc (ABCL) has a 20-day trading average at $3.02 and the current price is -65.84% off the 52-week high compared with 3.38% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.52 and its 200-day simple moving average is $4.47. If we look at the stock’s price movements over the week, volatility stands at 4.53%, which increases to 4.82% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 29.96 to suggest the stock is oversold.

The consensus objective for the share price is $14.62, suggesting that the stock has a potential upside of 81.19% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 22, 2024 when The Benchmark Company upgraded the stock to “Buy” and issued a price target of $9.

AbCellera Biologics Inc (ABCL) stock is down -7.09% over the week and -26.67% over the past month. Its price is -51.84% year-to-date and -56.83% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.11 above consensus estimates by 0.02. The company’s next earnings report forecasts estimating quarterly EPS at -0.14 and -0.57 for whole year. Expected sales for next quarter are $10.89M, which analysts say will come at $41.49M for the current fiscal year and next year at $52.63M. In addition, estimates put the company’s current quarterly revenue at an average of $10.15M.

To reach the target analysts have set, the stock logically needs to grow 81.19 percent from here.

The company has a return on investment of -12.26% and return on equity of -12.56%. The beta has a value of 0.38. Price to book ratio is 0.71 and price to sales ratio is 22.59.